Effects of GLP-1RAs on Fertility Outcomes in Obese Women With PCOS
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-40
SponsorPeking University Third Hospital
About this trial
The goal of this clinical trial is to examine whether GLP1-RA and healthy lifestyle education in women with PCOS and obesity prior to fertility treatment improves live birth rate and other reproductive, maternal and perinatal outcomes compared to metformin plus healthy lifestyle education.
Eligibility criteria
Qualifiers
Women with a wish to conceive;
Women with PCOS (Rotterdam criteria);
28 kg/m2≤BMI<35kg/m2;
Age: 18-40 years old
Disqualifiers
Women with diseases unsuitable for pregnancy or any other contraindications to infertility treatment Endocrine disorders; Abnormalities in liver and kidney function; Other medications such as glucocorticoids, anti-androgen drugs ;(spironolactone, cyproterone acetate, flutamide, etc.) within the last 3 months; Acute infections, severe cardiovascular disease, malignant tumors; Ongoing weight loss therapy (>5% weight loss in the last 3 months) or history of gastrointestinal surgery; Uterine abnormalities that may affect assisted reproductive outcomes, untreated hydrosalpinx Male azoospermia, severe oligozoospermia and asthenospermia, or patients receiving donor sperm treatment Chromosomal abnormalities, patients planning preimplantation genetic testing (PGT) or donor oocyte treatment History of recurrent miscarriag Allergic to or contraindicated for GLP-1 class medications.
Trial design
Treatments tested in this trial
- GLP-1 receptor agonist
- Metformin
Treatment groups
406 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov